NYEE HomeThe New York Eye and Ear Infirmary
Patient InfoHealthcare ProfessionalsSpecialties & ServicesSupport NYEEAbout Us
  Current Research
Clinical Trials in Ophthalmology
Ophthalmology
Research

Otolaryngology
Research

Pathology
& Laboratory Medicine
Research

Plastic &
Reconstructive
Surgery
Research

Institutional
Review Board
(IRB)

 
printer-friendly version of this pagePrinter-Friendly Page large print version of this pageLarge Print Version 

A Phase IV, Open Label, Multi-Center, Trial of Maintenance Intravitreous Injections of MacugenŽ (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated with a Modality Resulting in Maculopathy Improvement, EOP 1023

Principal Investigator: Richard Rosen, MD  

Enrollment Status: Open  

Objective:  The objective of this trial will be to explore the safety and efficacy of intravitreous injections of MacugenŽ (pegaptanib sodium) when given every 6 weeks for 48 weeks in subjects with exudative maculopathy who, after previous treatment regimen, have improved based upon clinical and anatomical (OCT) findings as determined by the investigator.

Eligibility:  Contact Principal Investigator/Coordinator. 

Contact Information:  

  • Principal Investigator: Richard Rosen, MD at (212) 979-4284
  • Study Coordinator: Peggy Guerrero, MD,CRC (212)-979-4671
  • Katy Tai, CR Manager (212) 979-4251

 

Home > Current Research > Clinical Trials in Ophthalmology > A Phase IV, Open Label, Multi-Center, Trial of Maintenance Intravitreous Injections of MacugenŽ (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated with a Modality Resulting in Maculopathy Improvement, EOP 1023